Working actively with emotion has been empirically shown to be of central importance in psychotherapy, yet has been underemphasized in much of the writing on cognitive-behavioral therapy (CBT). This state-of-the-art volume brings together leading authorities to describe ways to work with emotion to enrich therapy and achieve more robust outcomes that go beyond symptom reduction. Highlighting experiential techniques that are grounded in evidence, the book demonstrates clinical applications with vivid case material. Coverage includes mindfulness- and acceptance-based strategies, compassion-focus.

Longitudinal compression of a velocity-tailored, intense neutralized K{sup +} beam at 300 keV, 25 mA has been demonstrated. The compression takes place in a 1-2 m drift section filled with plasma to provide space-charge neutralization. An induction cell produces a head-to-tail velocity ramp that longitudinally compresses the neutralized beam, enhancing the beam peak current by a factor of 50 and producing a pulse duration of about 3 ns. This measurement has been confirmed independently with two different diagnostic systems.

Key scientific results from recent experiments, modeling tools, and heavy ion accelerator research are summarized that explore ways to investigate the properties of high energy density matter in heavy-ion-driven targets, in particular, strongly-coupled plasmas at 0.01 to 0.1 times solid density for studies of warm dense matter, which is a frontier area in high energy density physics. Pursuit of these near-term objectives has resulted in many innovations that will ultimately benefit heavy ion inertial fusion energy. These include: neutralized ion beam compression and focusing, which hold the promise of greatly improving the stage between the accelerator and the target chamber in a fusion power plant; and the Pulse Line Ion Accelerator (PLIA), which may lead to compact, low-cost modular linac drivers.

Due to their ease of production and safety, plasmid-based vaccines have become prime candidates for both prophylactic and therapeutic human vaccination. In experimental animal models, vaccination with plasmid DNA expression vectors has been shown to induce robust cellular and humoral immune responses against a variety of infectious diseases and some cancers. However, DNA vaccines have proven to be weakly immunogenic in human clinical trials. The poor immunogenicity of DNA vaccines in humans necessitates the development of novel methods to enhance both cellular and humoral immune responses against the plasmid-encoded antigen(s). Previous in vivo studies have shown that CD4+CD25+Foxp3+ T regulatory cells can repress antigenspecific immune responses. We demonstrate here that depletion of CD25+ cells prior to plasmid vaccination significantly enhances primary and memory T cell responses and antibody responses to a model DNA vaccine against Lymphocytic choriomeningitis virus. If this approach can be safely applied to humans it may not only improve the clinical utility of DNA vaccines but also improve conventional vaccines as well.